The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Peter P. Pfreundschuh net worth and biography

Peter Pfreundschuh Biography and Net Worth

CFO of Frequency Therapeutics

Peter is Frequency Therapeutics’ Chief Financial Officer. He joined Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as Chief Financial Officer, Chief Compliance Officer and Corporate Secretary. He brings to Frequency more than 20 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries. Prior to joining UroGen, Peter was the CFO of Sucampo Pharmaceuticals Inc., where he co-led the sale of the company to Mallinckrodt, was EVP and CFO of Immunomedics Inc., and was CFO of the heart pump maker, CircuLite Inc. Pfreundschuh also has held senior roles across finance, commercial operations and business development within the pharmaceutical industry at AstraZeneca Pharmaceuticals and Johnson & Johnson. He started his career as an auditor at Ernst & Young, LLP.

Peter is a certified public accountant and holds a Master of Business Administration in finance from Rider University. He has completed master’s coursework in strategic marketing from Northwestern University’s Kellogg School of Management and received his Bachelor of Science in accounting from Rutgers University. Mr. Pfreundschuh is currently on the Boards of Speratus Therapeutics Inc., and GitBasic.

What is Peter P. Pfreundschuh's net worth?: The estimated net worth of Peter P. Pfreundschuh is at least $44,770.13 as of October 3rd, 2023. Mr. Pfreundschuh owns 149,433 shares of Frequency Therapeutics stock worth more than $44,770 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Pfreundschuh may own. Learn More about Peter P. Pfreundschuh's net worth.
How do I contact Peter P. Pfreundschuh?: The corporate mailing address for Mr. Pfreundschuh and other Frequency Therapeutics executives is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. Frequency Therapeutics can also be reached via phone at 781-315-4600 and via email at [email protected]. Learn More on Peter P. Pfreundschuh's contact information.
Has Peter P. Pfreundschuh been buying or selling shares of Frequency Therapeutics?: Peter P. Pfreundschuh has not been actively trading shares of Frequency Therapeutics during the last quarter. Most recently, Peter P. Pfreundschuh sold 1,542 shares of the business's stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $3.53, for a transaction totalling $5,443.26. Learn More on Peter P. Pfreundschuh's trading history.
Who are Frequency Therapeutics' active insiders?: Frequency Therapeutics' insider roster includes Carl LeBel (Insider), Christopher Loose (Insider), Quentin McCubbin (Insider), and Peter Pfreundschuh (CFO). Learn More on Frequency Therapeutics' active insiders.
Are insiders buying or selling shares of Frequency Therapeutics?: During the last twelve months, insiders at the sold shares 46 times. They sold a total of 65,319 shares worth more than $36,102.94. The most recent insider tranaction occured on August, 18th when VP Richard J Mitrano sold 227 shares worth more than $143.01. Insiders at Frequency Therapeutics own 16.8% of the company. Learn More about insider trades at Frequency Therapeutics.
Information on this page was last updated on 8/18/2023.

Peter P. Pfreundschuh Insider Trading History at Frequency Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/22/2022	Sell	1,542	$3.53	$5,443.26
2/18/2022	Sell	1,404	$3.88	$5,447.52
2/15/2022	Sell	1,347	$4.33	$5,832.51

Peter P. Pfreundschuh Buying and Selling Activity at Frequency Therapeutics

Frequency Therapeutics Company Overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $0.30

$0.28

$0.32

50 Day Range

MA: $0.58

$0.22

$14.98

2 Week Range

Now: $0.30

$0.18

$16.00

Volume

309,164 shs

Average Volume

822,537 shs

Market Capitalization

$10.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Move Your Money Before May 22

From Stansberry Research | Ad